CXCL12 and Miyoshi myopathy: We measured cEPCsand stromal cell-derived factor-1α (SDF-1α) in 46 MM patients in the first cycle oftreatment with bortezomib and dexamethasone, and investigated clinical relevancebased on patient response after four 21-day cycles.